Mauricio Burotto

Also affiliated with Clínica Alemana, Finis Terrae University

MedicineBiochemistry, Genetics and Molecular BiologyEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial”.

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

ESMO Open(2020)10.1136/esmoopen-2020-001079

N/A

6.4DataRank · unranked

524 citations

Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy +15 more

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

Cancer(2022)10.1002/cncr.34180

N/A

5.5DataRank · unranked

265 citations

David F. McDermott, Bernard Escudier, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers +20 more

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

European Urology(2021)10.1016/j.eururo.2021.10.001

N/A

2.6DataRank · unranked

80 citations

Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy +17 more

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

ESMO Open(2024)10.1016/j.esmoop.2024.102994

N/A

1.9DataRank · unranked

94 citations

Mauricio Burotto, Bernard Escudier, Andrea B. Apolo, María T. Bourlon, Amishi Y. Shah +15 more

Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial

European Journal of Cancer(2022)10.1016/j.ejca.2022.09.020

N/A

0.795DataRank · unranked

18 citations

Thomas Powles, Bernard Escudier, Mauricio Burotto, Joshua Zhang, Burçin Şimşek +4 more

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

Annals of Oncology(2025)10.1016/j.annonc.2025.09.006

N/A

0.719DataRank · unranked

18 citations

Bernard Escudier, Mauricio Burotto, Thomas Powles, Andrea B. Apolo, María T. Bourlon +16 more

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Annals of Oncology(2024)10.1016/j.annonc.2024.07.727

N/A

0DataRank · unranked

198 citations

Laurence Albigès, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers +20 more